Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioCity Starts China Phase II Trial of ETA-Receptor Antagonist for Kidney Disease

publication date: Jun 22, 2023

BioCity Biopharma, located in Wuxi, China, will start a China Phase II trial of its novel oral endothelin A (ETA)-receptor selective antagonist, enrolling two patients with IgA nephropathy (IgAN). The multi-center study will be a randomized, placebo-controlled trial that assesses the safety and preliminary efficacy of SC0062 compared to placebo in patients suffering from chronic kidney disease with albuminuria. BioCity's Phase I trial showed a favorable safety profile in healthy subjects. The company has already started a separate Phase II trial of SC0062 for IgAN with diabetic kidney disease. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital